Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.
Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.

Start Date01 Jan 2026

Sponsor / Collaborator

University of Zurich

[+2]

NCT06832683

/ Not yet recruitingNot ApplicableIIT

Comparison of the Efficacy of Intravenous Propofol-Ketamine and Sevoflurane Administered Via Face Mask in Children Undergoing Magnetic Resonance Imaging: A Prospective, Randomized, Parallel-Group Study

Magnetic resonance imaging (MRI) is becoming increasingly important in the diagnosis and follow-up of pediatric diseases. However, successful MRI requires complete and prolonged immobility, which can be challenging for young children and infants. To overcome this challenge, various anesthesia techniques are employed by anesthesiologists. The ideal anesthesia method for children during MRI should be both safe and enable rapid recovery, allowing the child to remain still during the procedure while minimizing risks during the recovery period.
**Sevoflurane has become a popular choice for this purpose due to its rapid onset, limited respiratory side effects at low concentrations, reduced airway irritation, and hemodynamic stability. However, propofol and ketamine, used as an alternative sedation method, are also being increasingly utilized during these procedures. The major side effects of propofol include respiratory depression, apnea, loss of protective reflexes, and hemodynamic instability. To minimize these side effects, some experts recommend the combined use of propofol and ketamine. This combination provides effective sedation while also contributing to a reduction in side effects.
In this context, the aim of our study is to compare the efficacy of intravenous propofol and ketamine with sevoflurane administered via a face mask during pediatric MRI.

Start Date01 Jul 2025

Sponsor / Collaborator-

NCT06457958

/ WithdrawnPhase 4IIT

The Effect of Sevoflurane and Desflurane Anesthetic Agents Used in Elective Cholecystectomy Surgery on Heme Oxygenase-1 MRNA Expression and Heme Oxygenase-1 Protein Levels: a Comparative Prospective Study

General anesthesia is routinely administered to patients who undergo elective cholecystectomy. The most commonly used inhalation agents during general anesthesia are sevoflurane and desflurane. Participants who will undergo elective cholecystectomy surgery and meet the eligibility criteria will be randomized. Participants will be divided into two groups. One group will receive sevoflurane, and the other group will receive desflurane. Preoperative and postoperative blood samples will be taken from the participants. After the sample collection process is completed, the ELISA method will be used for measuring blood heme oxygenase-1 protein levels, and the PCR technique will be used for measuring blood heme oxygenase-1 mRNA gene expression. The increase in amounts between the two groups will be compared. This study aims to demonstrate the effects of the most commonly used inhalation agents on the levels of heme oxygenase-1 enzyme, which has been shown to be an important enzyme in cellular protection mechanisms, as well as on mRNA gene expression, and to determine which agent may be more effective in preventing cellular damage at the molecular level.

Start Date01 Jun 2025

Sponsor / Collaborator

Türkiye Bilimsel ve Teknolojik Arastirma Kurumu

100 Clinical Results associated with GlyR

100 Translational Medicine associated with GlyR

0 Patents (Medical) associated with GlyR

3,079

Literatures (Medical) associated with GlyR

01 Dec 2025·Journal of Clinical Immunology

Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) Associated with GlyR Antibody in an APECED Patient

Letter

Author: Lionakis, Michail S ; Leite, M Isabel ; Waters, Patrick ; Vieillard, Eléonore ; Ochoa, Sebastian ; Soldatos, Ariane

01 Jun 2025·Forensic Science International: Genetics

Kinship cases with partially specified hypotheses

Article

Author: Egeland, Thore ; Vigeland, Magnus Dehli

Forensic kinship testing is the statistical comparison of a set of hypothesised relationships, based on genetic marker data from the individuals in question and possibly other relatives. In most circumstances each hypothesis is completely specified in terms of a pedigree, but this is not always the case in more complex scenarios. For example, suppose that we are asked to test H₁: A is the grandmother of B, against H₂: A and B are unrelated, and that the data also includes a third individual whose relationship with the others is uncertain. There may then be multiple pedigrees consistent with each hypothesis, with the consequence that the standard likelihood ratio (LR) cannot be calculated unless prior probabilities are specified for all alternatives. In response to these challenges we introduce a generalised likelihood ratio (GLR), defined as the ratio of the maximal likelihood of the data given H₁ to the maximal given H₂. This resembles a version of the LR test used in classical hypothesis testing, but differs in several aspects. Most importantly, in the forensic setting we usually consider discrete alternatives rather than continuous parameter spaces. The properties of the GLR statistic are explored through real-life examples of kinship testing and disaster victim identification (DVI). In particular, we demonstrate how the GLR may help to resolve and report the results in complex DVI cases. As a final application we demonstrate how the GLR can be used to check correctness of pedigree data, an essential quality control step in projects involving genotypes from related individuals. Unlike the other examples, this one operates over a continuous parameter space, enabling tools from classical statistics to guide decision-making.

01 Jun 2025·Molecular Metabolism

Molecular correlates of glycine receptor activity in human β cells

Article

Author: Ellis, Cara E ; MacDonald, Patrick E ; Schukarucha Gomes, Amanda ; Maghera, Jasmine ; Dos Santos, Theodore ; Spigelman, Aliya F ; Suzuki, Kunimasa

OBJECTIVESGlycine acts in an autocrine positive feedback loop in human β cells through its ionotropic receptors (GlyRs). In type 2 diabetes (T2D), islet GlyR activity is impaired by unknown mechanisms. We sought to investigate if the GlyR dysfunction in T2D is replicated by hyperglycemia per se, and to further characterize its action in β cells and islets.METHODSGlyR-mediated currents were measured using whole-cell patch-clamp in human β cells from donors with or without T2D, or after high glucose (15 mM) culture. We also correlated glycine-induced current amplitude with transcript expression levels through patch-seq. The expression of the GlyR α1, α3, and β subunit mRNA splice variants was compared between islets from donors with and without T2D, and after high glucose culture. Insulin secretion from human islets was measured in the presence or absence of the GlyR antagonist strychnine.RESULTSAlthough gene expression of GlyRs was decreased in T2D islets, and β cell GlyR-mediated currents were smaller, we found no evidence for a shift in GlyR subunit splicing. Glycine-induced currents are also reduced after 48 h culture of islets from donors without diabetes in high glucose, where we also find the reduction of the α1 subunit expression, but an increase in the α3 subunit. We discovered that glycine-evoked currents are highly heterogeneous amongst β cells, inversely correlate with donor HbA1c, and are significantly correlated to the expression of 92 different transcripts and gene regulatory networks (GRNs) that include CREB3(+), RREB1(+) and ZNF697(+). Finally, glucose-stimulated insulin secretion is decreased in the presence of the GlyR antagonist strychnine.CONCLUSIONSWe demonstrate that glucose can modulate GlyR expression, and that the current decrease in T2D is likely due to the receptor gene expression downregulation, and not a change in transcript splicing. Moreover, we define a previously unknown set of genes and regulons that are correlated to GlyR-mediated currents and could be involved in GlyR downregulation in T2D. Among those we validate the negative correlation between EIF4EBP1 expression and GlyR activity.

News (Medical) associated with GlyR

04 Jan 2023

·www.prnewswire.com

Sedana Medical receives FDA Fast Track Designation in the United States

STOCKHOLM, Jan. 4, 2023 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the evaluation of isoflurane via the Sedaconda ACD-S device for sedation of mechanically ventilated patients in the intensive care (ICU) setting. Fast Track is a process designed to facilitate the development, and expedite the review of therapies that treat serious conditions and fill an unmet medical need. The purpose is to get important new therapies to the patient earlier. Clinical programs with Fast Track Designation may benefit from frequent communication with the FDA throughout the development and review process and may be eligible to Accelerated Approval and Priority Review if relevant criteria are met. Another possible benefit may be a Rolling Review, which means that completed sections of the New Drug Application (NDA) can be submitted for review by FDA, rather than waiting until every section of the NDA is completed. "The FDA's decision to grant Fast Track Designation underscores the potential for our product candidates to address a serious unmet need and bring meaningful benefits to ventilated patients in intensive care. We are fully committed to work even more closely with FDA to bring our therapy to US patients as soon as possible," said Johannes Doll, CEO of Sedana Medical. "This excellent news represents an important step forward in our highest potential market." Sedana Medical is aiming for a combination registration of the medical device Sedaconda ACD and the pharmaceutical isoflurane for sedation of mechanically ventilated intensive care patients in the United States. Two identical Phase III studies, INSPiRE-ICU 1 and 2, are ongoing with the objective to confirm the efficacy and safety of inhaled sedation with isoflurane delivered via Sedaconda ACD in intensive care. Sedana Medical will engage in discussions with the FDA on how the development program can benefit from the FTD. At present, the guidance regarding the timeline is unchanged: assuming rapid enrolment of patients and successful trials, Sedana Medical expects the NDA submission in 2024 and a launch in early 2025. About the studies INSPiRE-ICU 1 and INSPiRE-ICU 2 (SED003 and SED004) The INSPiRE-ICU (Inhaled Sedation vs Propofol in Respiratory failure) studies are two identical phase III studies aiming to confirm the efficacy and safety of inhaled isoflurane, delivered via the Sedaconda ACD, for the sedation of adult mechanically ventilated ICU patients, in comparison to intravenous infusion of propofol. The studies will enrol a total of 470 adult patients across 25-30 sites in the US. Patient enrolment is expected to be completed in 2023. The primary endpoint is the proportion of time spent within the target range of sedation depth in absence of rescue sedation, as assessed according to the Richmond Agitation Sedation Scale (RASS). In addition, the studies will investigate several secondary endpoints, including the use of opioids, the wake-up time, the cognitive recovery after end of sedation, and the spontaneous breathing effort. The assessments will be performed by blinded assessors to meet the requirements of the FDA. Further information on the studies is available at (NCT05312385 for SED003 and NCT05327296 for SED004). For additional information, please contact: Johannes Doll, CEO, +46 76 303 66 66 Johan Spetz, CFO, +46 730 36 37 89 [email protected] Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm. The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, [email protected] About Sedana Medical Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors. Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden. The following files are available for download: SOURCE Sedana Medical

Phase 3Fast TrackNDA

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

GlyR

Basic Info

Related

Analysis